Related Experiment Video
Updated: Mar 20, 2026

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis
Published on: August 15, 2025
Structural characterization and antidiabetic activity of a glucopyranose-rich heteropolysaccharide from Catathelasma
Yuntao Liu1, Di Chen2, Yuxian You2
1Key Laboratory of Animal Disease-Resistance Nutrition, Animal Nutrition Institute, Sichuan Agricultural University, Chengdu 611130, China; College of Food Science, Sichuan Agricultural University, Yaan 625014, China.
Abstract:
Polysaccharides, which are the main bioactive constituents of edible mushrooms, have been shown to have a variety of useful biological activities. In this study, a polysaccharide fraction from the edible mushroom Catathelasma ventricosum was purified using anion exchange and size exclusion chromatographies. The structure of the resulting polysaccharide, named CVP-1S, was characterized on the basis of partial acid hydrolysis, periodic acid oxidation, methylation analysis, gas chromatography-mass spectrometry, Fourier-transform infrared spectroscopy, 1D/2D NMR spectroscopy, scanning electron microscopy, and atomic force spectroscopy. The results showed that CVP-1S is a heteropolysaccharide consisting of glucose (94.2%), galactose (3.51%) and fucose (1.3%) with a molecular weight of 1.5×10(4)Da. Its backbone is mainly linked by (1→6)-β-d-Glcp glycosidic bonds, and branches are attached to the backbone through 1,3-linked glycosidic bonds. CVP-1S was also found to have antioxidant, hypoglycemic, and hypolipidemic activities in the streptozoicin-induced diabetic mouse model. From these results, we conclude that CVP-1S should receive further attention as a potential agent for the treatment and prevention of diabetes.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Chemistry of Carbohydrates
Cellulose and Pectic Polysaccharides
As a cell matures, its cell wall specializes according to its type. For example, the...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

